Pages that link to "Q82877400"

The following pages link to Cancer: the road to Amiens (Q82877400):

Displaying 44 items.

• Moving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial design (Q26830525) (← links)
• Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer (Q28396304) (← links)
• Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience (Q33399986) (← links)
• Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics (Q33514878) (← links)
• The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer (Q33689293) (← links)
• Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience (Q33899157) (← links)
• Targeting oncogenic protein-protein interactions by diversity oriented synthesis and combinatorial chemistry approaches. (Q33915473) (← links)
• It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy (Q33936071) (← links)
• Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy. (Q33947959) (← links)
• PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers (Q33987852) (← links)
• Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience (Q34252383) (← links)
• Fool's gold, lost treasures, and the randomized clinical trial (Q34669260) (← links)
• PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors (Q34769343) (← links)
• Melanoma genotypes and phenotypes get personal (Q34788817) (← links)
• Greater patient access to immuno-oncology therapies-what can policymakers do? (Q35125347) (← links)
• Combining targeted therapies: practical issues to consider at the bench and bedside (Q35583672) (← links)
• Cooperative Group Cancer Clinical Trials: An NCIC Clinical Trials Group Perspective (Q35605711) (← links)
• Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development (Q35838562) (← links)
• Personalized therapy in endometrial cancer: challenges and opportunities (Q35911350) (← links)
• Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials (Q36534696) (← links)
• Compliance in early-phase cancer clinical trials research (Q36714394) (← links)
• A Patient Focused Solution for Enrolling Clinical Trials in Rare and Selective Cancer Indications: A Landscape of Haystacks and Needles (Q37124478) (← links)
• Cancer drugs in the United States: Justum Pretium--the just price (Q37195250) (← links)
• Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial (Q37220383) (← links)
• Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors (Q37493954) (← links)
• Taking the long view: how to design a series of Phase III trials to maximize cumulative therapeutic benefit (Q37522787) (← links)
• Evaluation of Cross-Calibrated 68Ge/68Ga Phantoms for Assessing PET/CT Measurement Bias in Oncology Imaging for Single- and Multicenter Trials (Q37558197) (← links)
• An appraisal of drug development timelines in the Era of precision oncology (Q37619700) (← links)
• Targeted therapy in non-small-cell lung cancer--is it becoming a reality? (Q37765472) (← links)
• Translating Clinical Trials into Meaningful Outcomes (Q37822198) (← links)
• Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team. (Q38524536) (← links)
• Targeted polytherapy in small cell sarcoma and its association with doxorubicin (Q38977714) (← links)
• Molecular characterization of interdigitating dendritic cell sarcoma (Q41382659) (← links)
• "First do no harm" and the importance of prediction in oncology. (Q41731147) (← links)
• A Bayesian adaptive design for biomarker trials with linked treatments (Q41835806) (← links)
• Factors related to biopsy willingness in patients with advanced cancer in a phase 1 clinic for molecularly targeted therapy (Q43679493) (← links)
• A cancer trial scandal and its regulatory backlash (Q46349887) (← links)
• Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists (Q51249026) (← links)
• The inverted pyramid of biomarker-driven trials (Q51689988) (← links)
• Clinical Development of Vascular Disrupting Agents: What Lessons Can We Learn From ASA404? (Q52613053) (← links)
• The importance of greater speed in drug development for advanced malignancies. (Q52618970) (← links)
• Randomized Phase II Trials: Misleading and Unreliable (Q53074049) (← links)
• The role of nonrandomized trials in the evaluation of oncology drugs (Q86716365) (← links)
• New drug approvals in oncology (Q89532708) (← links)